Standard BioTools Inc. (LAB) Market Cap & Valuation Ratios
Standard BioTools Inc. (LAB) has a market cap of $237.7M and a price-to-sales ratio of 2.8, with earnings according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
LABStandard BioTools Inc.Follow LAB — free
—
Price chart with a free account
- Market cap
- 237.7M
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 10 Nov, in 17 days
Peers
medical devices · nearest by market cap · trailing 12 months| Company | Mkt cap, $B | P/E | EV/Sales | EV/EBITDA | FCF yield | Rev. growth | Op. margin | ROIC |
|---|---|---|---|---|---|---|---|---|
| LAB | 0.2 | — | — | — | — | -5% | -113% | -36% |
| OFIX | 0.4 | — | 0.6 | 37.9 | -7.0% | +3% | -5% | -7% |
| VMD | 0.4 | 27.2 | 1.2 | 7.0 | 7.8% | +25% | 8% | 12% |
| CV | 0.3 | — | 24.5 | — | -8.0% | +11% | -217% | -737% |
| QSI | 0.3 | — | 121.3 | — | — | -53% | — | -62% |
| CLPT | 0.3 | — | 7.1 | — | -11.2% | +26% | -73% | -160% |
| TMCI | 0.3 | — | 1.4 | — | -9.0% | -4% | -26% | -42% |
| RXST | 0.2 | — | — | — | -13.0% | -4% | -36% | -23% |
| INGN | 0.2 | — | 0.2 | — | -5.1% | +3% | -9% | -34% |
| CATX | 0.2 | — | — | — | — | — | — | -49% |
| MXCT | 0.1 | — | 1.2 | — | — | -13% | -135% | -26% |
| Median of these 10 | 27.2 | 1.3 | 22.4 | -8.0% | +3% | -31% | -38% |
.
Growth vs. price
each dot a company · hover or tap for valuesStandard BioTools Inc. — questions
- What is Standard BioTools Inc.'s market cap?
- $237.7M.
- What is Standard BioTools Inc.'s price-to-sales ratio?
- 2.8.
Every figure on this page comes from Standard BioTools Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.